A previous study using a computational approach found a stronger predicted progression on the Matthias Dementia Rating Scale for patients with variants in EGFr domains 7–34 (i.e., predominantly MR and LR-NOTCH3 variants), compared with patients with EGFr domains 1–6 (i.e., HR-NOTCH3 variants).29 This is in contrast to our results, as we found no single neuroimaging, clinical, or cognitive outcome which progressed faster in the MR-NOTCH3 group than in the HR-NOTCH3 group. This evidence concerns the gene EGFR and dementia.